EBS Emergent BioSolutions Inc

Price (delayed)

$2.15

Market cap

$111.39M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$12.08

Enterprise value

$925.99M

Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through their specialty products and contract development and manufacturing services, the company is dedicated ...

Highlights
EBS's quick ratio has shrunk by 72% YoY but it is up by 15% QoQ
EBS's gross profit has dropped by 57% year-on-year but it is up by 26% since the previous quarter
The net income has plunged by 51% from the previous quarter
EBS's EPS is down by 50% since the previous quarter

Key stats

What are the main financial stats of EBS
Market
Shares outstanding
51.81M
Market cap
$111.39M
Enterprise value
$925.99M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.11
Price to sales (P/S)
0.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.86
Earnings
Revenue
$1.07B
EBIT
-$478.6M
EBITDA
-$343.2M
Free cash flow
-$358.7M
Per share
EPS
-$12.08
Free cash flow per share
-$7.07
Book value per share
$18.96
Revenue per share
$21.18
TBVPS
$26.98
Balance sheet
Total assets
$2.18B
Total liabilities
$1.22B
Debt
$903.2M
Equity
$956.3M
Working capital
$84.5M
Liquidity
Debt to equity
0.94
Current ratio
1.12
Quick ratio
0.55
Net debt/EBITDA
-2.37
Margins
EBITDA margin
-32%
Gross margin
33.5%
Net margin
-56.6%
Operating margin
-51%
Efficiency
Return on assets
-21.7%
Return on equity
-48.7%
Return on invested capital
-25.1%
Return on capital employed
-32.2%
Return on sales
-44.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EBS stock price

How has the Emergent BioSolutions stock price performed over time
Intraday
6.97%
1 week
2.87%
1 month
7.5%
1 year
-81.73%
YTD
-81.8%
QTD
-36.76%

Financial performance

How have Emergent BioSolutions's revenue and profit performed over time
Revenue
$1.07B
Gross profit
$360M
Operating income
-$548.1M
Net income
-$608M
Gross margin
33.5%
Net margin
-56.6%
EBS's operating income has plunged by 68% from the previous quarter
EBS's gross profit has dropped by 57% year-on-year but it is up by 26% since the previous quarter
The company's operating margin has shrunk by 53% QoQ
The net income has plunged by 51% from the previous quarter

Growth

What is Emergent BioSolutions's growth rate over time

Valuation

What is Emergent BioSolutions stock price valuation
P/E
N/A
P/B
0.11
P/S
0.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.86
EBS's EPS is down by 50% since the previous quarter
The price to book (P/B) is 95% lower than the 5-year quarterly average of 2.1 and 78% lower than the last 4 quarters average of 0.5
EBS's equity is down by 37% year-on-year and by 20% since the previous quarter
The P/S is 95% below the 5-year quarterly average of 2.1 and 80% below the last 4 quarters average of 0.5
The company's revenue fell by 33% YoY but it rose by 10% QoQ

Efficiency

How efficient is Emergent BioSolutions business performance
EBS's return on equity has dropped by 67% since the previous quarter
The company's return on assets has shrunk by 58% QoQ
EBS's ROIC has shrunk by 56% QoQ
EBS's ROS is down by 32% since the previous quarter

Dividends

What is EBS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EBS.

Financial health

How did Emergent BioSolutions financials performed over time
The total assets is 78% more than the total liabilities
EBS's quick ratio has shrunk by 72% YoY but it is up by 15% QoQ
Emergent BioSolutions's current ratio has plunged by 71% YoY but it has increased by 12% from the previous quarter
Emergent BioSolutions's debt is 6% lower than its equity
The debt to equity has soared by 71% YoY but it has decreased by 19% QoQ
EBS's equity is down by 37% year-on-year and by 20% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.